Znanstveni rad - Izvorni znanstveni rad
Use of cerebrospinal fluid biomarker analysis for improving Alzheimer's disease diagnosis in a non-specialized setting

Malnar, Martina; Kosicek, Marko; Bene, Raphael; Petek Tarnik, Iva; Pavelin, Sanda; Babic, Ivana; Brajenović - Milić, Bojana; Hecimovic, Hrvoje; Titlic, Marina; Trkanjec, Zlatko; Demarin, Vida; Hecimovic, Silvia (2012)
Podaci o radu
Jezik rada engleski
Naslov (engleski)Use of cerebrospinal fluid biomarker analysis for improving Alzheimer's disease diagnosis in a non-specialized setting
AutorMalnar, Martina
Kosicek, Marko
Bene, Raphael
Petek Tarnik, Iva
Pavelin, Sanda
Babic, Ivana
Brajenović - Milić, Bojana
Hecimovic, Hrvoje
Titlic, Marina
Trkanjec, Zlatko
Demarin, Vida
Hecimovic, Silvia
Sažetak rada (engleski)
Low levels of amyloid-β42 (Aβ42) and high total-tau (t-tau) or phosphorylated-tau (p181-tau) levels in cerebrospinal fluid (CSF) were shown to be characteristic for Alzheimer’s disease (AD) patients and for mildly cognitively impaired (MCI) or non-demented individuals who will progress to AD. The goal of this study was to evaluate the benefit of CSF biomarker testing in a setting with no specialized dementia centers, in order to improve the accuracy of AD diagnosis and to identify individuals with incipient AD. Using ELISA assay we analyzed CSF Aβ42, t-tau and p181-tau levels among clinically diagnosed non-demented individuals, AD patients and individuals with uncertain dementia (n=36). CSF cut-off values of low Aβ42 (≤530 pg/mL) and high t-tau (≥350 pg/mL) or p181-tau (≥52 pg/mL) were used to identify individuals with AD/ MCI-CSF profile, regardless of clinical diagnosis. APOE genotyping was performed using PCR-RFLP method. In accord with previous studies we detected significantly decreased levels of CSF Aβ42 and increased tau and p181-tau levels in clinically diagnosed AD group vs. non-demented controls. CSF profiling identified individuals with a typical AD/MCI-CSF pattern in clinically referred non-demented group (9%) and among patients with uncertain dementia (41.7%). APOE ε4-allele was associated with the CSF biomarker changes typical for AD. This study shows that in a non-specialized setting CSF biomarker testing may be used as a screening tool for improving the accuracy of AD diagnosis and for predicting individuals with incipient Alzheimer’s disease who need to receive further clinical follow-up.
Ključne riječi (engleski)Alzheimer’s disease amyloid-β, biomarkers cerebrospinal fluid diagnosis tau
Vrsta radaznanstveni rad - izvorni znanstveni rad
Status objave radaobjavljen
Vrsta recenzijerecenziran
Naslov časopisaActa Neurobiol Exp
Brojčani podaci2012, Vol. 72, br. 3, str. 264-271
e-ISSN1689-0035
Datumdatum objave publikacije: 2012.
URL radahttp://www.ane.pl/pdf/7224.pdf
Znanstveno područjeBIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Neurologija
UstanovaSveučilište u Rijeci, Medicinski fakultet
(Katedra za biologiju i medicinsku genetiku)
URN:NBNhttps://urn.nsk.hr/urn:nbn:hr:184:933151